TheCareerBridge.com’s Post

Oral Oncology

Enhancing the Data Journey in Oncology Clinical Trials

Approaching Kaplan-Meier (KM) plots in oncology trials requires a critical eye, considering three key peculiarities: late divergence, survival curve crossings, and censoring imbalances. Let’s focus on censoring. Many oncology journals, except Lancet, often neglect to report censored patient data at specific intervals. This omission creates gaps in understanding the imbalances between control and experimental arms, raising doubts about the 'R' in RCTs. Standard survival analysis methods lose validity under these circumstances. For instance, if early censoring occurs in the experimental group but not in the control group, it can falsely inflate the intervention's perceived effectiveness. This distortion often arises when the experimental oncology treatment is excessively toxic, allowing only relatively healthier patients to continue on the intervention arm, skewing the results of the time-to-event analysis in favor of the intervention. Indeed, these censoring imbalances might explain the prevalence of approved drugs showing significant effects on Progression-Free Survival but minimal impact on Overall Survival. Approach KM plots skeptically, anticipate censoring imbalances, and avoid assuming the integrity of uninformed censoring for accurate interpretations.

New report out now: Hematologic Cancer Opportunities for Patient Equality (HOPE): Geographic Disparities in Access, Reimbursement, and Hematology Therapy Utilization. Hematological cancer incidence is projected to increase by 55% by 2050, from 1.3 million in 2022 to 2.03 million in 2050. Yet trends in hematological malignancy access aren’t as well understood as oncology patient access. This report showcases: ✅ Trends regarding the availability of therapies for hematological malignancies across selected countries. ✅ Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analyzed for drugs. ✅ A comparison of these trends with similar ones for solid tumors. ✅ Important dynamics associated with hematology, such as the prevalence of combination therapies and approval based on Phase I/II or III data. ✅ Potential drivers of these trends and the challenges faced by hematology drugs. ✅ The implications of these findings and provides a call to action for policies. Download the report here: https://bit.ly/3xoV81c #Hematology #HealthEquity #GlobalHealth #IQVIAMIDAS

🩸 New report out now: Hematologic Cancer Opportunities for Patient Equality (HOPE): Geographic Disparities in Access, Reimbursement, and Hematology Therapy Utilization. Hematological cancer incidence is projected to increase by 55% by 2050, from 1.3 million in 2022 to 2.03 million in 2050. Yet trends in hematological malignancy access aren’t as well understood as oncology patient access. This report showcases: ✅ Trends regarding the availability of therapies for hematological malignancies across selected countries. ✅ Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analyzed for drugs. ✅ A comparison of these trends with similar ones for solid tumors. ✅ Important dynamics associated with hematology, such as the prevalence of combination therapies and approval based on Phase I/II or III data. ✅ Potential drivers of these trends and the challenges faced by hematology drugs. ✅ The implications of these findings and provides a call to action for policies. Download the report here: https://bit.ly/4bZ2kAd #Hematology #HealthEquity #GlobalHealth

Interesting report! hematologic cancers - geographic disparities in access, reimbursement and therapy utilization This report aims to quantify the trends regarding the availability of therapies for hematological malignancies across selected countries with reported oncology therapy access challenges and disparities. Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analyzed for drugs indicated in hematological malignancies.

𝗜𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿 𝘁𝗵𝗲𝗿𝗲 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗾𝘂𝗶𝘁𝗲 𝘀𝗼𝗺𝗲 𝗮𝗰𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆. 📈 🧬Therapeutic focused areas of most active buyers: 💰 Novartis closed 4 deals across the following: Oncology and Autoimmune/Inflammatory 💰Johnson & Johnson Innovative Medicine closed 3 deals across Oncology and Inflammatory Diseases 💰Merck Group have also closed 3 deals. Two of them being in oncology and one in ophthalmology 💰AstraZeneca following up the pattern with 2 deals. One being in Oncology and the other in Endocrine Disease 💰AbbVie also close 2 deals in Autoimmune/Inflammatory 🔎𝗪𝗵𝗮𝘁 𝘄𝗶𝗹𝗹 𝘄𝗲 𝘀𝗲𝗲 𝗶𝗻 𝗛𝟮 𝗼𝗳 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿? : There is a clear focus on oncology and autoimmune diseases which should remain key areas, with high premiums for promising early-phase assets... Let me know your thoughts in the comments below ⬇️ #Biotech #BioPharma #BioNews #MasonHarding

BridGene CEO Dr. Ping Cao discusses the company's approach to hard-to-drug targets in this interview posted by The Clinical Trial Vanguard. #DrugDiscovery #Biotechnology #Pharmaceuticals #Innovation #Chemoproteomics #Oncology #Immunology #Neurology #BridGeneBiosciences #HealthcareInnovation

OdigosHUB is #hiring for our collaborated #cancer company Do share your resume at odigostraining@gmail.com or call Krishna yadav 8452025846 #odigoshub #hiring #hiringnow #jobs #jobalert #clinicaltrial #clinicaloperations #clinical #clinicaljobs #clinicaloperations #pharmacovigilance #datamanagement #commercialoperation #clinicaldatamanagement #clinicalevaluation #cancerresearch #cancer #cancertreatment #cancerbiology

You deserve a partner with the pharmacology knowledge, tools and experience to help move your oncology drug candidates through discovery, preclinical and beyond. #PreclinicalOncology #FastStudyStarts #FastTrackDiscovery #Oncology #OncologyDrugs #OncologyBiologics